CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV infection, the company said on Tuesday.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization ...

E xecutives at Gilead Sciences, the biotech behind a long list of HIV treatments and preventative medicines, have spoken with ...

Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

CVS Health, one of the nation’s largest pharmacy benefit managers, has declined to cover Gilead’s newly FDA-approved HIV ...

At the International AIDS Society meeting this year, a young woman from South Africa spoke. She is the first Black woman from ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading below its intrinsic value. See more.

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.